SHR-9839

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameSHR-9839
Drug Alias NameSHR-9839SHR9839
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A